Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz

WOBURN, MA / ACCESSWIRE / April 26, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that that the last

Related Keywords

United States ,Biofrontera Bioscience Gmb , ,Twitter ,Biofrontera Inc ,Biofrontera Inc View ,Skin Cancer Foundation ,Nasdaq ,Biofrontera Bioscience Gmbh ,Erica Monaco ,Chief Executive Officer ,Biofrontera ,Nnounces ,Mast ,Patient ,Hase ,Study ,Valuate ,Safety ,Tolerability ,Reating ,Ctinic ,Keratosis ,Sing ,Tubes ,Ameluz ,